Loading patent…
AssigneeObi Pharma, Inc.
InventorsCheng-Der Tony YU, Youe-Kong SHUE, Chen-Hsin LIANG, Peiwen YU, Chwen-Cheng CHEN
Estimating the term…
The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against Globo series antigens (i.e., Globo H, Stage-specific embryonic antigen 3 “SSEA3” and Stage-specific embryonic antigen 4 “SSEA4”). Specifically, the method comprises administering Globo H-KLH (OBI-822) in patients with Metastatic Breast Cancer. The disclosure also provides a method of comprises selecting a cancer patient who is suitable as treatment candidate for immunotherapy. In addition, the disclosure provides therapeutic agents, including monoclonal antibodies (mAbs) that bind specifically to Globo series antigens and related biomarkers useful in focusing such therapeutic and diagnostic regimens.
A method for treating a breast cancer comprising administering to a subject in need thereof a therapeutically effective dose of Globo series antigens vaccine and/or cross-reacting with Globo series antigens vaccine.
A method for treatment of a tumor in a patient, comprising administering to the patient a pharmaceutically effective amount of Globo series antigens vaccine and/or cross-reacting with Globo series antigens vaccine.
A method for treating a subject with afflicted with cancer by immunotherapy comprising administering to subject in need thereof a therapeutically effective amount of an immunogenic agent and/or cross-reacting with the immunogenic agent useful for inducing or modulating an immune response.
A method for inducing/enhancing an immune response in a subject, comprising administering to the subject in an immunogenic agent and/or cross-reacting with the immunogenic agent.
A method of improving OBI-822 vaccine induced immune-responsiveness in a subject in need thereof comprising:
A method for identifying a suitable patient for cancer therapy in need thereof comprising:
Dependencies are inferred from the claim text.